Pathogenesis of Type 2 Diabetes Mellitus by AlSaraj, Fuad
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Pathogenesis of
Type 2 Diabetes Mellitus
Fuad AlSaraj
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/59183
1. Introduction
The natural history of type 2 diabetes (T2DM) has been well described in multiple populations.
Patients with T2DM have inherited genes from parents that make their tissues resistant to
insulin. Insulin resistance (IR) in muscle and liver and β-cell failure represent the core
pathophysiologic defects in development of T2DM. Age, genes, IR, lipotoxicity, glucotoxicity,
amyloid deposition and abnormal incretin are factors playing a role in progressive β-cells
dysfunction. The progressive decline in insulin secretion, decrease of the pancreatic β- cell
mass and function and the presence of IR will contribute in changing the state of the dysgly‐
cemia from normal to, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and
end with overt diabetes [1].
2. Glucose metabolism
Excessive hepatic glucose output is an important factor in the fasting hyperglycemia of patients
with T2DM. Following administration of isotope in healthy subjects and in patients with
T2DM, the overall hepatic glucose output was an increase by twofold and the gluconeogenesis
more than threefold in patients compare with the controls. This finding demonstrated the
increased in gluconeogenesis is the predominant mechanism responsible for increased hepatic
glucose output in patients with T2DM and it is correlated with fasting plasma glucose level.
[2]. Insulin controls the hepatic glucose production and promotes glucose utilization by the
skeletal muscle. There is a correlation between the hepatic glucose production and the fasting
glucose, in normal subjects, the postabsorptive hepatic glucose production is increased. But in
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patients with T2DM, the main causes are increased mostly by gluconeogenesis and to less
extent by glycogenolysis by the liver. The Increased production of gluconeogenic precursors
(lactate, alanine, and glycerol) and hyperglucagonemia with increased hepatic FFA acid
oxidation might be responsible for glucogenesis. There is also a reduction in suppression of
hepatic glucose production after carbohydrate ingestion which plays a role in the impairment
in postprandial glucose homeostasis in T2DM [3].
The increased of the glycogenolysis and the decreased in the hepatic glucose uptake by
glucagon will produce hyperglycemic phenotype associated with insulin deficiency and IR.
In the overnight fasted, it is essential in countering the suppressive effects of basal insulin to
maintain appropriate levels of glycogenolysis, fasting hepatic glucose production and blood
glucose. Glycogenolysis is also increased by the counter-regulatory hormones response to
hypoglycemia and in exercise [4]. Insulin and glucagon secretion are determined by plasma
glucose concentration which is widely fluctuated according to the demand such as exercise
and supply as taking high carbohydrate meal. In the resting postabsorptive state, the glyco‐
genolysis and gluconeogenesis are equal or in balance in hepatic glucose release. This is a key
regulated process. In the postprandial state, suppression of liver glucose output and stimula‐
tion of skeletal muscle glucose uptake are the most important factors. Under stressful condi‐
tions, the counter-regulatory hormones of the hypoglycemia secretion are increased with
increased of the sympathetic nervous system activity. Their actions to increase hepatic glucose
output and to suppress tissue glucose uptake are partly mediated by increases in tissue fatty
acid oxidation. In T2DM, the fasting hyperglycaemia resulted from increased gluconeogenesis
while, the postprandial hyperglycemia occurs due to impaired suppression of glycogenolysis
and impaired skeletal muscle glucose uptake [5].
In normal subjects the fasting plasma glucose levels are constant from day to day. This
constancy is due to a close co-ordination between glucose production by the liver and glucose
uptake in peripheral tissues. In T2DM, fasting hyperglycemia to less extent is correlated with
increased hepatic glucose production due to impaired hepatic sensitivity to insulin. But, it is
largely due to reduced insulin secretion and increased glucagon secretion. Though the basal
immunoreactive insulin and glucagon levels in patients with T2DM may appear normal
compared with the normal subjects, the islet function testing at matched glucose levels reveals
impairments of the basal, steady-state, and stimulated insulin and glucagon secretion due to
a reduction in β- cells secretory capacity and a reduced ability of glucose to suppress glucagon
release. Islet α- and β-cells functions are reduced by more than 50% in T2DM by the time that
clinical fasting hyperglycemia develops (140 mg/dL) [6]. The efficiency of glucose uptake by
the peripheral tissues is also impaired due to a combination of decreased insulin secretion and
defective of the cellular insulin action [6, 7]. The defective in first phase glucose induced insulin
secretion is followed by fasting hyperglycemia and the progressive failure in pancreatic β-cells
function is matched by rising glucose levels to maintain basal and second-phase insulin output.
The glucose is not only directly regulated insulin synthesis and secretion. But, moderated all
other islet signals, including other substrates, hormones, and neural factors. In T2DM the
defects are in first-phase insulin secretion and in the deficiency of the ability of glucose to
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potentiate other islet nonglucose β-cell secretagogues. In T2DM patients, the resulting
hyperglycemia does not correct the first phase of insulin secretion defect. However, it com‐
pensates for the defective glucose potentiation, maintains nearly normal basal insulin levels
and insulin responses to nonglucose secretagogues [8].
The major primary reduction of suppression in the output of the endogenous hepatic glucose
release and the minor effect of the splanchnic glucose sequestration in these patients are the
cause of increasing in systemic glucose delivery which subsequently responsible for the
postprandial hyperglycemia [9, 10].
The fasting hyperglycemia is mainly caused by the increased of the released hepatic glucose
production. This mechanism is increased in psotabsorptive state and exhibits a positive
correlation with fasting glucose level [3, 7 11].
The increase of the glucogenesis in the postprandial state represents the primary mechanism
responsible for impaired suppression of hepatic glucose production [3]. The increased in the
rate of glucose release by the liver results in part from impaired hepatic sensitivity to insulin,
but it is largely due to reduced insulin secretion and increased glucagon secretion [6]. The
degree of fasting hyperglycemia in a given patient with T2DM is closely related to the degree
of impaired pancreatic β-cells responsiveness to glucose.
The fasting insulin secretion in normal subject and in patients with T2DM is comparable. But,
there is a marked impairment of insulin secretion in patients with DM in relation to the degree
of hyperglycemia. This is demonstrating the closed feedback loop operating between glucose
levels and pancreatic β-cells which regulates the relationship of insulin secretion and hepatic
glucose production [11]. The glucose uptake by peripheral tissue is impaired due to a combi‐
nation of decreased insulin secretion and defective in cellular insulin action [6, 7].
The amyloid deposition process is associated with disproportionate hyperproinsulinemia. The
amylin in transgenic mice develops islet amyloid deposits and hyperglycemia. This is sug‐
gestive the process of amyloid fibril formation impairs the function of the β-cells and eventual
death. The progressive loss of β-cell function in T2DM, initially reflected by the loss in first-
phase insulin secretion, followed by a decrease in the maximal capacity of glucose to potentiate
all non-glucose signals. Finally, a defective steady-state and basal insulin secretion develops,
leading to complete β-cells failure requiring insulin therapy [12].
The conclusion is, T2DM is characterized by a steady-state re-regulation of plasma glucose
concentration at an elevated level in which islet cells dysfunction play a necessary role [7].
3. Insulin secretion, function and impairment
Insulin is synthesized and produced by β- cells in the pancreas. It is a peptide hormone
regulates the metabolism of fat and carbohydrate in the body. It helps glucose absorption from
the circulation by fat tissue and skeletal muscles. Figures 1 [13] and 2 [14].
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Figure 1. Insulin secretion [13].
Figure 2. Insulin functions [14].
Pancreatic β-cells secrete insulin in two phases, first and second phase (biphasic manner). The
loss of first phase is an independent predictor of T2DM onset. In patients with T2DM, the
restoration of this phase suppresses the hepatic glucose output and improves the blood glucose
concentration [15]. There are many metabolic abnormalities precede the clinical picture of
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T2DM as demonstrated in a study of normal first- degree subjects who had relatives with
T2DM. Following intravenous glucose infusion, these subjects showed a reduced first phase
insulin secretion with decreased ability of the β-cells to respond to successive increase or
decrease in glucose with mild elevation in 2hours post challenge glucose level [16]. In patients
with T2DM, the earliest detectable defect and exhaustion of β- cells function appeared in the
reduction of the first-phase insulin secretion. This phase is brief burst and spike lasting for
about 10 minutes followed by plateau second phase lasted for 2-3 hours. The reductions in
both phases occur equally early and precede development of IR [17]. The fasting plasma insulin
concentration is often a marker of insulin sensitivity (IS) and the changing in acute insulin
secretion following glucose challenge is an early observation of progressive pancreatic defect.
Glucotoxicity and lipototoxicity are contributor factors in progressive and the continuous
decline in pancreatic function [1, 18].
Insulin is secreted from the secretory cells by priming reaction. Each cell contains thousands
of secretory vesicles/granules. Less than <5% of these cells exist to release the readily pool
insulin by exocytosis followed by minimal latency of immediate releasable pool of insulin. The
bulk of granules in the cell (>95%) exist in a non-releasable reserve pool of insulin, which must
undergo a series of ATP-, Ca2+-, and temperature-dependent reactions to release insulin [19].
The prevalence of Gestational diabetes (GDM) is 2-3% of all pregnant women. GDM women
have the same second –phase insulin response as women with normal oral GTT. But, the first
phase-insulin secretion is reduced with intravenous glucose and has a later peak rise with
OGTT. Both groups showed a decreased in IS by 50-70%, this is back to normal in postpartum
period in women with normal OGTT but this is not in women with GDM. In the same period,
the latter group also demonstrated a persistent and excessive proinsulin secretion. Women
with GDM have also a substantial increase in insulin secretion with OGTT or a meal compared
to the same women in postpartum period. But this rise is less in women with GDM compared
with pregnant women who retain normal OGTT [20].
The glycemic progression from normal to IGT mainly due to IR and from this state to overt
DM depends primarily on β-cells failure in addition to progression to severe IR. Two studies,
San Antonio and Hoorn Study showed the high fasting proinsulin reflects the β-cells dysfunc‐
tion and the progression to DM. IR is determined by fasting hyperinsulinemia and lower
glucose removal. Therefore, the 2 hours blood glucose level following oral glucose load is the
most powerful in prediction of development of T2DM. IR and progressive β-cells dysfunction
are the two important defects in development of the disease [21]. IFG and IGT are intermediate
states in glucose metabolism that exist between normal GT and overt diabetes are related to
these defects in addition to the reduction in early-phase insulin secretion. But, subjects with
IGT also have impaired late-phase insulin secretion. The latter group also demonstrated a
significant higher muscle IR and low hepatic IR while subjects with IFG have severe hepatic
IR with normal or near-normal muscle IS [22]. The insulin secretion and glucose homeostasis
in the first phaase insulin secretion is determined by a complex pathawy of multiple signals
including hypoxia inducible factor 1α, von Hippel-Lindau, factor inhibiting HIF, nicotinamide
phospho-ribosyl-transferase, and the sirtuin family in addition to many other novel regulatory
factors are crucial [15].
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4. Insulin resistance
Patients with T2DM have high whole body glucose production and glucogenesis but low
glycogenolysis compared with normal subjects. In patients with IR, there is impairment of
glucose transport and insulin signaling in target tissues with release of inflammatory markers
from the adipose tissue [23, 24]. The glucose, FFA, autonomic nerves, fat-derived hormones
and the gut hormone glucagon-like peptide-1 (GLP-1) are mediators sending signals to the β-
cells to respond to IR. The maintenance of normal glucose and lipid metabolism is by the
reciprocal relation of IR to IS and insulin secretion. Hyperbolic relation is the best description
of the curvilinear relation between IS and secretion. This relation is impaired with failure of
these signals to act on β-cells to secret insulin ends with subsequent development of dysgly‐
cemia (Impaired Fasting glucose- IFG, impaired Glucose tolerance –IGT and DM) [25].
Obesity is the most common cause of IR and T2DM. Simply being overweight (BMI >25) raises
the risk of developing T2DM by a factor of 3 [26].
The main components of IR are dysglycemia, dyslipidemia, obesity, hypertension and
hyperinsulinemia. Therefore, it is the key feature of metabolic syndrome (MS) and vascular
complications (cardiovascular and stroke). IR components once are acquired, those with
genetic predisposition will develop the full picture of the disorder suggesting the final
phenotypic expression involves both genetic and acquired influences. The most important
environmental factor in IR is central obesity which is mainly caused by intake of high fat, and
refined carbohydrate without physical activity. These are exacerbated by genetic predisposi‐
tion but IR could be reduced with minimizing dietary intake and regular exercise [27].
The three potential mechanisms of the controlling glucose metabolism in the skeletal muscles
are the glycogen synthase, the hexokinase and the major insulin-stimulated glucose trans‐
porter GLUT4. Therefore, defects in glycogen synthesis in the skeletal muscles playing a major
role in the pathogenesis of IR [28]. The decrease in the ability of normal responding skeletal
muscles to circulating insulin levels or concentrations is main principle of development of IR
which could precede the overt T2DM by 10 to 20years [28].
T2DM is characterized by increased hepatic glucose output, increased peripheral resistance to
insulin action (due to receptor and postreceptor defects) and impaired insulin secretion.
Two major variants of insulin receptor abnormalities associated with acanthosis nigricans,
hyperinsulinemia and marked hyperandrogenism. The classic type A IR syndrome, which
is  due to  genetic  defect  in  the  insulin-signaling system such as  mutation in  the  insulin
receptor gene [29] and type B IR syndrome, which results from autoantibodies to the insulin
receptor [30].
Many factors could enhance IR include, obesity, inflammation and inflammatory markers,
defects in genes and drugs. These will be demonstrated further in this chapter.
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5. The role of obesity and inflammatory markers in insulin resistance and
T2DM
Obesity has a substantial negative effect on life expectancy and longevity. It reduces the length
of life in severely obese people by an estimation of 5 to 20 years. This negative effect should
be addressed in the health public policy [31]. Obesity, IR, and T2DM are growing health
concerns, and the incidence and the prevalence of these diseases are increasing worldwide [32,
33]. Obesity will cause a decline in life expectancy for the first time in recent history due to
numerous co-morbid disorders [31] and it is a risk factor for many human diseases [34]. Obesity
is associated with an increased risk of developing IR and T2DM [34, 35]. The primary defects
in obese individuals are the dysfunction of adipocyte and adipose tissue [34].
IR in obese subjects is determined by the release of high amounts of non-esterified FA, glycerol,
hormones, pro-inflammatory cytokines and many other factors from adipose or fat tissue. This
is followed by dysfunction of pancreatic β- cells and failure to secret insulin to control blood
glucose levels. These metabolic and inflammatory changes are critical in defining the risk and
the development of T2DM. [35]. There is a clear hyperbolic relationship between IS and insulin
secretion by the β-cells of the pancreas. This demonstrates the concept of a feedback loop
governs the interaction between the β-cells function and IS tissues. This helpful in explain that
patients or subjects with IR have significant increase in insulin response compared with low
responses in IS group [11, 36].
IR is a characteristic feature of T2DM and obesity, and the majority of patients with T2DM are
obese. Obesity has a major impact to cause IR in subjects without DM. IR is the primary defect
in obese elderly and middle aged patients with T2DM despite, adequate circulating insulin.
But, in the second group the impairment of insulin release and the alteration of hepatic glucose
output are other defects contributing to the development of the disease [37, 38, 39]. The intra-
abdominal fat is a major determinant of IR among other distributed fat in the body while the
dysfunction of the β- cells is correlated with reduction of β-cells mass and subsequently
reduction in IS. The genetic and the molecular basis of these pathological abnormalities are
there. But, not fully understood. As mentioned, the progressive declining or failure of the β-
cells function and IS are associated with development of T2DM. Prior to the onset of T2DM,
there are stages from normal glucose concentration to dysglycemia (IFG, IGT) emphasizing in
number of ethnic group the OGTT response is a major determinant of β-cells function [25, 36].
The elevations in plasma FFA concentrations in obese subjects and in patients with T2DM
inhibit insulin stimulated peripheral glucose uptake (fat and skeletal muscle) and glycogen
synthesis [40, 41].
The impairment of adipose tissue functions in obese subjects caused by interaction of genetic
and environmental factors and subsequently leads to obesity medical co-morbidities. How‐
ever, not all obese patients develop the same complications. The adipocyte dysfunctions or
impairment occur in form of ectopic fat deposition, adipocyte hypertrophy, hypoxia, changes
in the cellular composition with a variety of stresses and inflammatory processes in the fat
tissue (release a proinflammatory, atherogenic, and diabetogenic adipokine pattern), increased
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lipid storage and impaired IS [33]. Obese individuals have large or expanded fat mass and
have high or elevated plasma concentration fatty acids [42, 43, 44].
Glucose uptake rather than intracellular glucose metabolism has been implicated as the rate-
limiting step for FA-induced IR [45].
In adipose tissue, the glucocorticoids can be produced locally from inactive 11-keto forms
through the enzyme 11beta hydroxysteroid dehydrogenase type 1 (11beta HSD-1). In obese
human, the glucocorticoids are normal. However, the excess of glucocorticoids produce
visceral obesity, IR and DM. In mice, the transgenic mice overexpressing 11beta HSD-1
selectively in adipose tissue was exaggerated by high fat diet showed an increase in the level
of corticosterone in adipose tissue by increased adipocyte 11beta HSD-1 activity. This could
have the same effect in human[46] suggesting that increases in endogenous 11β-HSD1 in the
adipose tissue of obese humans and rodents [47,48] contribute to obesity-associated IR, in part
due to increased delivery of glucocorticoids to the liver via the portal vein. The c-Jun amino-
terminal kinases (JNKs) interfere with insulin action and it is crucial mediator of obesity and
IR. In obese mouse, the JNK activity is abnormally elevated and the absence of JNK1 results
in decreased adiposity and improved IS. Therefore, it is a potential target for therapeutics [49].
The activation of JNK1 leads to serine phosphorylation of IRS-1 that impairs insulin action [50,
51]. In addition, IKK-β is a mediator of TNF-induced IR [52, 53, 54, 55] demonstrated the TLR4
(Lipopolysaccharide receptor) activation by FFA, plays a critical role in innate immunity and
IR in obese human and animals through activation of inflammatory pathways. In mice the lack
of TLR4 will protect insulin suppression signaling and reduce insulin mediated changes in
systemic glucose metabolism by lipid infusion. This indicates the effect of nutrition as
environmental factor on TLR4 and subsequently on IR. The Apoptosis signal-regulating kinase
1 (ASK1) is an evolutionarily conserved mitogen-activated protein 3-kinase that activates both
Jnk and p38 mitogen-activated protein kinases. The reactive oxygen species-dependent
TRAF6-ASK1-p38 axis is crucial for TLR4-mediated mammalian innate immunity [53, 54]. This
finding may provide an additional link between innate immunity, cellular stress, and IR. The
protein tyrosine phosphatase receptor T (PTPRT) knockout mice are resistant to high-fat diet-
induced obesity. The PTPRT-modulated STAT3 signaling in the regulation of high-fat diet-
induced obesity [34]. Figures 3 and 4 with Table 1.
Adipokine Distribution Function Effect in obesity
Leptin
Secreted predominantly by
WAT, to lesser degree, in
ypothalamus, gastric epithelium,
placenta & gonads.
Regulates energy intake,
expenditure & feeding
behavior.
Also regulates storage of fat &
insulin signaling.
↑  in mouse models of obesity.
↑  in human obesity & correlated
with BMI & ↓  in weight loss.
Adiponektin
Secreted exclusively by
adipocytes. mRNA & protein in
Sc AT > Omental AT.
Improves energy homeostasis,
IS & Glucose uptake.
Anti-Inflammatory properties.
↓  in mouse models of obesity and
IR (ob/ob and db/db).
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Adipokine Distribution Function Effect in obesity
2–3 times greater secretion in
females.
↓  in human obesity & T2DM
patients.
↑  after weight loss
Resistin
In rodents, secreted by
adipocytes.
In humans, secreted
predominantly by circulating
macrophages & monocytes, to a
lesser degree, by WAT.
Implicated in glucose
metabolism, in the regulation
of gluconeogenesis & IR in
rodents.
More roinflammatory role in
humans.
↑  circulating concentrations in
mouse models of obesity.
↑  in human obesity & correlated
with IR in T2DM patients.
TNF-α
Expressed by macrophages &
adipocytes (visceral WAT >
subcutaneous WAT).
Affects insulin & glucose
metabolism. Provokes IR &
stimulates lipolysis.
↑  in mouse models of obesity.
↑  in human obesity & correlated
with BMI
IL-6
One-third of total circulating
levels are expressed
predominantly by adipocytes.
Also expressed in macrophages,
skeletal muscle, endothelial cells
& fibroblasts.
Controversial role in the
development of IR.
Affects glucose metabolism
↑  circulating levels in human obese
subjects & correlated with
adiposity& reduced with weight
loss.
↑  in plasma of T2DM patients.
IL-7 Secreted by stromal & vascularendothelial cells.
Homeostatic immune
cytokine. Also regulates body
weight, AT mass & function,
and insulin signaling.
↑  in morbidly obese subjects.
IL-8
Secreted by adipocytes (visceral
WAT > SC WAT) &
macrophages.
Neutrophil chemotaxis. ↑  in obese subjects & related to fatmass & TNF-α levels.
IL-1 Secreted mainly by adipocytes &macrophages.
Role in macrophages
chemotaxis & thermogenesis
↑  in obese mice.
↑  in human obesity & predictive of
T2DM.
IL-10
Secreted by monocytes,
macrophages, dendritic cells, B
& T cells.
Improves IS & glucose
transport.
Attenuated in T2DM patients & ↑
with weight loss
RBP4 Secreted by adipocytes,macrophages & hepatocytes.
Affects IS, hepatic glucose
output & muscle insulin
signaling.
↑  circulating levels in obese
subjects & correlated with BMI &
IR.
MCP-1 Secreted by AT.
Affects IS & ↑  macrophage
recruitment in AT and
inflammation.
↑  in mouse models of obesity.
↑  in T2DM subjects.
PAI-1 Expressed by WAT. Potent inhibitor of fibrinolyticpathway.
↑  in human obesity and T2DM
subjects.
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Adipokine Distribution Function Effect in obesity
CXCL5 Secreted by macrophages withinthe stromal vascular fraction.
Interferes with insulin
signaling in muscle.
Circulating levels are higher in
obese IR individuals than in obese
IS & ↓  after a 4-weeks period on
low-calorie diet.
Visfatin
Expressed in liver, muscle,
WAT, bone marrow &
lymphocytes
Role in IS, insulin secretion &
inflammatory properties.
↑  in obesity & correlates with
visceral adiposity in humans.
Chemerin In rodents & humans, expressedin placenta & WAT.
Regulates adipocyte
development & metabolic
function.
↑  circulating levels in obese &
T2DM patients and correlated with
body fat, glucose & lipid
metabolism.
Vaspin
Secreted by WAT,
hypothalamus, pancreatic islets
& skin.
Improves IS. ↑  in obesity & T2DM patients
Omentin Secreted by omental AT. ↑  IS ↓  in obesity.
Apelin Produced in a wide range oftissues.
Improves IS mainly acting in
skeletal muscle
& adipocytes in mice.
↑  in obesity, IGT & T2DM patients.
↓  after weight loss following diet &
bariatric surgery.
Nesfatin Secreted in brain tissue, Β cellsand AT.
Central action to
↓  Appetite. ↓  in obesity.
TGFβ
Multifunctional, produced
By variety of cells. Inhibitor of
differentiation.
Varied role in proliferation,
differentiation, apoptosis and
development.
↑  ob/ob and db/db mice.
↑  preadipocyte cell proliferation as
with TNFα. ↑  in obesity, T2DM
patients & CVD.
Rantes
Pro -inflammatory secreted by T
cells, monocytes & to lesser
degree in WAT.
↑  gene expression in AT. No correlation of serum level withobesity.
Preptin
It is a novel hormone that is co-
secreted with insulin and amylin
from pancreatic β-cells [60].
Synthetic prepin ↑  insulin
secretion from glucose
stimulated β TC6-F7 in a
concentration- dependent and
saturable manner [61].
Plasma preptin level ↑  with higher
BMI [62].
It is ↑  in patients with T2DM
compared with patients with IGT
and normal subjects [61].
Uncoupling
protein 2
It is expressed in AT, skeletal
muscle and tissue of immune
system [63].
It protects cell function from
damage and it impairs insulin
secretion from β-cells [64].
Anti-oxidant in pancreatic β-cells
[65].
The level and activity has impact
on glucose stimulated insulin
secretion [66].
Table 1. Adipokines increased in obesity and/or diabetes [58, 59].
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Figure 3. The molecular linked pathway between obesity and IR. (A) IR triggered by the increase in FAs through intra‐
cellular metabolites that activate PKC, leading to inhibit insulin signaling by activation of serine/threonine kinases. (B)
Insulin signaling modulated by changes in adipokines secretion. (C) In the adipose tissue; the increased in the ATMs
mediated the increase of the inflammatory cytokines that inhibit insulin signaling. (D) Insulin signaling inhibited by
mediators (Endocrine and Inflammatory) converging on serine/threonine kinases. (E) IR exacerbated by activation of
NF-κB heightens inflammatory responses. (F) Adipokines induced SOCS family proteins interfering with IRS-1 and
IRS-2 tyrosine phosphorylation or by targeting IRS-1 and IRS-2 for proteosomal degradation inducing IR. (G) IR trig‐
gered by activation TLR4 and innate immune response by FAs. (H) Alteration in peripheral IS is related to the central
response to hormonal and nutrient signals [57].
Figure 4. There are several cell-intrinsic mediators and pathways dysregulation in obesity with negative impact on IR.
(A) Activation of PKC in the liver and muscles inhibits insulin signaling by increasing FA from ectopic adipose tissue.
(B) Direct inhibition of insulin signaling through IRS-1 or IRS-2 serine phosphorylation or indirectly through a series of
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transcriptional events mediated by NF-κB. Inhibition occurs due to activation of several serine/threoning kinases (JNK,
IKK, and p38 MAPK) by excess in ROS. The later generation increased by mitochondrial β- oxidation triggered by ex‐
cess fat accumulation. (C) IR exacerbated by mitochondrial dysfunction through increasing intracellular lipid accumu‐
lation. (D) Insulin signaling suppressed by activation of JNK or through a potential increase in ROS production and
both activated by cellular ER stresses responses. (E) The cell-extrinsic modulators such as endocrine and inflammatory
signals can intensified IR [57].
WAT: White adipose tissue, AT: adipose tissue, T2DM: type 2 diabetes mellitus, IR: insulin
resistance, IS: insulin sensitivity, IGT: impaired glucose tolerance, TNF-α: tumor necrosis
alpha, IL: interleukin, RBP4: Retinol binding protein, SC: subcutaneous, MCP-1: monocyte
chemotactic protein 1, PAI: plasminogen activator inhibitor, CXCL5: chemokines molecules
(CXCL5 ligand 5), TGFβ: transforming growth factor β.
6. Others
6.1. Glucose transporters
Glucose transporters (GLUT) are integral membrane proteins that mediate the transport of
glucose and structurally-related substances across the cellular membranes [67].
Sugar transport catalyzed by 11 out of 14 members of the human GLUT family. There are
specific characteristics of each isotypes. They are different in expression profile, substrate
specificity and kinetic characteristics. Therefore, the tissue adaptation of the glucose uptake
will be determined and regulated by specific tissue gene expression. GLUT4 malfunction in
expression or regulation contributes to IR while GLU2 plays a role in hormonal and neuronal
control by acting a glucose sensor in β-cells of the pancreas and neuronal cells [68]. GLUT1 is
ubiquitously expressed with particularly high levels in human erythrocytes and in the
endothelial cells lining the blood vessels of the brain. GLUT3 is expressed primarily in neurons
and, together, GLUT1 and GLUT3 allow glucose to cross the blood-brain barrier and enter
neurons [69].
The GLUTI, GLUT2, and GLUU3 are the major glucose transporters isoforms present in these
cells and they are constitutively localized to the plasma membrane. The glucose flux across
the membrane is largely dependent upon the circulating blood glucose level or concentration.
In acute state, the glucose regulated the transport system in the muscles and fat cells responded
within minutes to insulin [70].
GLUT4 is the primary hormonally-responsive transporter and it is the major insulin-respon‐
sive transporter [69]. GLUT4 expression is also reduced by low insulin states, such as in muscle
during fasting, and in IR adipose tissue [71]. The malfunction of glucose transporter expression
or regulation (GLUT4) appears to contribute to the IR syndrome [68].
7. Genes in type 2 Diabetes Mellitus
T2DM is a complex diseases arise from interactions of multiple genes with environmental
factors. These genes are variables in strength, site of interaction and are different in general
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population according to race and ethnicity. The diabetes genes are involved in insulin
signaling, insulin secretion, IR, glucose metabolism and obesity. In addition, T2DM could be
a component of many syndromes of identified inherited genes [72]. The genetic risk for T2DM
changes as humans first began migrating around the world, implying a strong environmental
component has affected the genetic-basis of the disease [73, 74]. Immigrants to Western
developed countries, for instance, may be more prone to diabetes as compared to its lower
incidence in their countries of origins [75]. In meta-analysis of different ethnicities was
included in a cross –sectional data from 16 cohorts from the DECODA (Diabetes Epidemiology:
Collaborative Analysis of Diagnostic Criteria in Asia) demonstrated; the waist-to-stature ratio
in Asian was stronger than BMI is associated with DM in adjusted age group in both genders
[76]. In Japanese-American the prevalence of DM was reduced among the men who had
retained a more Japanese lifestyle through higher levels of physical activity and consumed
more carbohydrates with less fat and animal protein in their diet. An inverse association
between DM and being bom in Japan was observed independent of age, body mass index,
physical activity, and percentages of calories from fat or carbohydrates [77]. In Fiji population
the disease pattern is determined by the modern lifestyle as in many industrial counties. The
increase in mortality in this population was contributing to 6% and 30% due to DM and CVD
respectively [78]. In USA, the large burden of T2DM in relative to non-Latino Whites, Latinos
—those of Mexican origin in particular is related to mixed acculturation to US lifestyles and
with greater time living in the States [79]. This was supported by other two studies. The first
showed IR, hyperinsulineamia and T2DM with secondary lipid disturbances are the possible
mechanism of higher morbidity and mortality from CHD in UK immigrants from the Indian
subcontinent (South Asian) than other general population independently of the dietary fat
intakes, smoking, blood pressure, or plasma lipids [80]. The second study also observed IR is
the common pathogenic mechanism and is a risk factor of increasing the prevalence of CHD,
T2DM, low HDL and hypertriglyceridemia in first generation immigrant Asian Indian to the
USA compared with native Caucasian population [81]. The two major environmental risk
factors for T2DM are obesity (≥ 120% ideal body weight or a body mass index > 30 k/m2) and
the sedentary lifestyle [82, 83]. Thus, the tremendous increase in the rates of T2DM in recent
years has been attributed, primarily, to the dramatic rise in obesity worldwide [84]. Obesity is
a progressive disease and up to 80% of patients with T2DM and PCOS patients can be
attributed to obesity. It is a progressive condition leads to medical co-morbidities which are
more prevalent with age and higher BMI, particularly in those with a central obesity [85]. In
Pima Indians adolescents, the prevalence of T2DM was 50.9 per 1000 in 1967-1976 increased
to 6 folds in 1987-1996. In American Indian and first nation youth, T2DM was more prevalent
in 10-19 years old young group. Mainly in obese subjects with acanthosis nigiricans and had
family history of the disease [86]. Sinha R, reported 25% of obese children (4 to 10 years of age)
and 21%t of obese adolescents (11 to 18 years of age) had IGT and 4% of the obese adolescent
has silent T2DM [87]. The increase in physical activity plays an important role in reducing risk
of obesity and T2DM. The prolonged TV watching is associated with a significantly increased
risk of obesity and T2DM, independent of diet and exercise. Men watching TV more than 40
hours per week have threefold of increase risk of developing T2DM compared with those less
than I hour TV watching. Therefore, the public health campaign of decrease sedentary life
should accompany the increase in physical activity [88].
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Physical activity has also been inversely related to body mass index and IGT. Interventional
studies in China, Finland and the US demonstrated the decrease in the risk of incidence and
in the progression from pre-diabetes stage (IGT) to T2DM by intensive lifestyle interventions
targeting diet and exercise. The Finnish Diabetes Prevention Study showed a reduction by 58%
and in the china study was 31% with diet and 42% with diet and exercise. This was supported
by USA study showed the same risk reduction with intensive lifestyle as in the Finnish study
and also a reduction of 31% with metformin indicating that lifestyle intervention is better than
drugs in T2DM prevention [89, 90, 91].
Xue Sun [92] reviewed a large-scale of association studies, and the genome-wide association
studies (GWAS). Both have successfully identified multiple genes that contribute to T2DM
susceptibility. Linkage analysis, candidate gene approach, large-scale association studies, and
GWAS have identified approximately 70 loci conferring susceptibility to T2DM. Among them,
45 loci were identified in European populations, and the other 29 loci were identified in Asian
populations, especially in East and South Asians. The immediate benefit derived from these
findings was the better understanding of the pathophysiology of T2DM. A great number of
studies have suggested that genetic variants in or near KCNJ11, TCF7L2, WFS1, HNF1B,
IGF2BP2, CDKN2ACDKN2B, CDKAL1, SLC30A8, HHEX/IDE, KCNQ1, THADA, TSPAN8/
LGR5, DC123/CAMK1D, JAZF1, MTNR1B, DGKB/TMEM195, GCK, PROX1, ADCY5, SRR,
CENTD2, ST6GAL1, HNF4A, KCNK16, FITM2-R3HDML-HNF4A, GLIS3, GRB14, ANK1,
BCAR1, RASGRP1, and TMEM163 may confer T2DM risk through impaired -β-cell function
[93-97] whereas PPARγ, ADAMTS9, IRS1, GCKR, RBMS1/ITGB6, PTPRD, DUSP9, HMGA2,
KLF14, GRB14, ANKRD55, and GRK5 have an impact on insulin action [94,98-100]. FTO and
MC4R, previously identified genes associated with obesity, appear to confer T2DM risk
through their primary effects on BMI, but recent GWAS have shown that their effects on T2DM
were independent of BMI, though FTO may have a small but detectable influence on T2DM
risk through insulin action [101,102].
Barnet AH; concluded the higher concordance rate in identical twins than in non-identical
twins regardless the age of the onset of the disease and in identical twins, the concordant for
DM is usually in older age group compared with the younger [103]. In Japan, The Concordance
between monozygotic twins was 83% for T2DM and was 40% between dizygotic twins for
T2DM. This concordance was significantly greater in monozygotic than in dizygotic twins and
among twins with later onset of DM (after the age of 20) than early onset. It was also observed,
the loss of the early-phase insulin response for OGTT in T2DM co-twins [104]. The role of
obesity or BMI in twins as a risk of DM varies in heterogeneous genetic background. The index
twins of concordant pairs had been less obese than discordant pairs. This is suggestive obesity
has a role in pathogenesis of DM in those with weaker genetic susceptibility for the disease [5].
Nonetheless, non diabetes first-degree relatives of T2DM patients have an almost three fold
increased lifetime risk of T2DM in comparison to the background population [106]. In other
study 40% of first-degree relatives of T2DM patients develop diabetes as compared to 6% in the
general population [106]. IR is an early metabolic feature of nondiabetic first-degree relatives
of T2DM patients [107,108] and also shows familial clustering in keeping with an underlying
genetic predisposition [109,110]. The defects of insulin action are retained in cultured skeletal
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muscle cells from IR subjects and T2DM patients [111,112] suggesting that genetic variation
contributes to decreased insulin action. While IR is a common feature of T2DM, the severity
and clinical importance varies considerably across the T2DM population [113].
7.1. Inherited DM: Maturity onset diabetes of the young or MODY
The transcription factor genes play a crucial role in the normal development and function of
the β-cell. MODY is a distinct type of heterogeneous group of disorders caused by mutations
in β-cell transcription factors. MODY is an autosomal dominant mode of inheritance β- cell
dysfunction in young age group (usually before 25 years). It is difficult to distinguish between
MODY and other forms of DM because of primary defect is pancreatic β-cell dysfunction in
patients with MODY. There are at least nine mutations of different gens that result in MODY
phenotypes which account in about 1-2% or 2-5% of patients diagnosed with DM (approxi‐
mately 20000 in UK). The transcription factors hepatocyte nuclear factor HNF - α1, HNF-4α,
insulin promoter factor (IPF)-1, HNF-1β, and NeuroD1 are the main identified genes in MODY.
The Glucokinase (GCK) is an enzyme responsible for glucose phosphorylation, whereas
HNF-1α, HNF-4α, IPF1, HNF-1β, and NEUROD1 are all transcription factors that modulate
the expression of several genes involved in differentiation and function of β-cells. This enzyme
is a key in blood glucose homeostasis and the defective in kinase gene metabolism implicated
in the pathogenesis of DM. There is a linkage between the GCK locus on chromosome 7p and
diabetes in 16 French families with MODY and the same linkage was demonstrated in a large
5-generation pedigree (BX) with 15 members with DM. Mutations in the GCK gene cause a
mild, asymptomatic and non-progressive fasting hyperglycaemia from birth usually requiring
no treatment. The gene on chromosome 7 (MODY2) encodes the glycolytic enzyme glucoki‐
nases plays a key role in generating the metabolic signal for insulin secretion and in integrating
hepatic glucose uptake. Other linkage studies have localized other genes mutation in MODY
on human chromosomes 20 (MODY1) and 12 (MODY3), with MODY2 and MODY3 being
allelic with the genes encoding glucokinase. MODY1 is an encoding (hepatocyte nuclear factor)
HNF-4α (gene symbol, TCF14), a member of the steroid/thyroid hormone receptor superfamily
and an upstream regulator of HNF-1 α expression. This is a transcription factor involved in
tissue-specific regulation of liver genes but also expressed in pancreatic islets, insulinoma cells
and other tissues. Mutations in the GCK and HNF1- α/4-α genes account for up to 80% of all
MODY cases, these mutations appear in different transcription factor genes result in different
clinical presentations. Mutations in the genes encoding the transcription factors HNF-1α and
HNF-4α cause a progressive insulin secretory defect and hyperglycemia while mutations in
the GCK gene cause a mild and non-progressive disease. MODY3 form has also mutations in
the gene encoding hepatocyte nuclear factor-1 α (HNF-1α, which is encoded by the gene TCF1).
Mutations in HNF-1α are highly penetrant with 63%of mutation carriers having diabetes by
the age of 25 years, 78.6% by 35 years, and 95.5% by 55 years resulted in progressive β- cell
dysfunction with increasing treatment requirements, greater risk of complications with age
and appear to be renal dysfunction, which is often diagnosed before diabetes. Mutations in
HNF-4α result in same mode of β- cell deterioration in β-cells function but the diagnosis in the
later age. Mutations in IPF-1 (PDX-1) are not a common cause of MODY. MODY1 form has
mutations in the gene encoding hepatonuclear factor HNF-4 α (gene symbol, TCF14) is a
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member of the steroid/thyroid hormone receptor superfamily and an upstream regulator of
HNF-1α expression. The deficient binding of NEUROD1 or binding of a transcriptionally
inactive NEUROD1 polypeptide to target promoters in pancreatic islets leads to the develop‐
ment of T2DM in humans. In mice, two mutations in NEUROD1 in the heterozygous state
were described in development of T2DM. The truncated polypeptide lacking the carboxy-
terminal trans-activation domain, a region that associates with the co-activators CBP and p300
is more severe clinically than mutation at Arg 111 in the DNA-binding domain, abolishes E-
box binding activity of NEUROD1 [114-125]. Other rare forms of MODY are CEL-MODY,
ABCC8, KCNJ11 and UPD6 [126]. There are many factors determined the clinical presentation
of various subtype of MODY including, the severity, the course of insulin secretion defect, the
risk of microvascular complications and the presence of other abnormalities or defects in
diabetes patients [127].
7.2. Mitochondrial diabetes: A monogenic Diabetes Mellitus
Maternally inherited diabetes and deafness (MIDD) is a new sub-type of diabetes with mutation
in mitochondrial DNA. The mitochondrial genome is passed and inherited exclusively by
maternal line. In patients with T2DM there could be increase in transmission of inherited diseases
by maternal line more than paternal. However, only 0.5-2.8% of patients with DM demonstrat‐
ed the frequency of adenine to guanine mutation. The adenine to guanine transition mutation
at position 3243 in the dihydrouridine loop of mitochondrial tRNALeu(UUR) gene is specific to
patients with a neurological syndrome MELAS (myopathy, encephalopathy, lactic acidosis and
stroke like disease). There is also 3243 mutation is associated with the phenotypical distinct of
MIDD sub-type. In a study of the genotype of patients with T2DM of North European extrac‐
tion with one or more features of MIDD and/or MELAS, Two patients were identified with the
mutation giving a prevalence rate of 0.13% for the whole study population, and 0.45% for the
sample with phenotypic features of MIDD. Other mitochondrial gene defects and mutation of
3234 are linked to the development of T2DM [128-133].
8. The monogenic forms of Insulin Resistance (IR)
A clear genotype-phenotype association is emerging following description of more than 60
mutations in insulin receptor gene which subsequently causing IR and tend to genera extreme
and severe forms of IR patients. The most abundant mutations are heterozygous leading to
decreased tyrosine phosphorylation of the β-subunit of the insulin receptor.
• Type A insulin resistance syndrome, it is a heterozygous mutations in the tyrosine kinase
domain of the insulin receptor gene and it is the most common phenotype. It is characterized
by acanthosis nigricans and hyperandrogenism without obesity or lipoatrophy.
• Homozygous or compound heterozygous mutations lead to the Rabson–Mendelhall
syndrome with severe impairment of insulin receptor function.
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• Donohue syndrome (Leprechaunism) is the most extreme form of IR in humans in whom
mutations resulting in complete or near-complete absence of functional insulin receptors.
[134,135,136]
• Dunnigan-type familial partial lipodystrophy (FPLD) is a rare autosomal dominant form of
monogenic IR. FPLD patients are born with normal fat distribution but after the onset of
puberty, they lose fat from their extremities and gluteal region. The mutation of LMNA,
which encodes nuclear lamin A and C on chromosome 1q21, underlies FPLD. These patients
have low leptin levels and FPDL is linked to early coronary heart disease. The LMNA codon
482 missense mutation was observed to strongly associated with hyperinsulinemia,
dyslipidemia, hypertension, and T2DM [137,138,139].
• The PPARγ gene, encoding the receptor through which the insulin-sensitizing drugs, the
thiazolidinediones, mediate their effects the peroxisome proliferator-activated receptor
gamma (PPARγ) has become a prime candidate in the search for mutations causing IR [140].
The new missense mutations in the ligand-binding domain of PPARγ were found in family
(mother and her son) was heterozygous for a single nucleotide substitution with mutation
at codon P467L. The mother had history of irregular period, infertility disorder, Gestational
DM followed by frank DM requiring high doses of insulin (severe IR). Her son had history
of early onset T2DM and hypertension. The third subject was a young female from another
family presented with primary amenorrhoea, hirsutism, acanthosis nigricans and hyper‐
tension. She was heterozygous from different mutation at codon V290 of a single nucleotide
substitution. These new subtypes of dominantly inherited T2DM due to defective tran‐
scription factor function resulting in impaired insulin action rather than secretion [141].
Studies to determine if mutations in the PPARγ gene predispose to diabetes in the general
population show a complex relationship.
8.1. Insulin gene
Several phenotypes, including T2DM, polycystic ovary syndrome, and birth weight are
associated with tandem repeat (VNTR) minisatellite 5' of the insulin gene (INS). A study
analyzed this insulin gene class III VNTR minisatellite in 155 European T2DM parent-offspring
trios from the British Diabetes Association demonstrated that variation within the TH-INS-
IGF2 locus, most plausibly at the VNTR itself at this regulatory element is a significant
determinant of T2DM susceptibility. This susceptibility is exclusively mediated by paternally
derived alleles [142].
8.1.1. SUR-1gene
In Dutch population, the exon 16-3t allele of the single nucleotide polymorphisms in the
sulphonylurea receptor gene (SUR1) has been reported to be associated with T2DM patients
compared with the control group. But there was no association between T2DM patients and
the variant in exon 18 or the combination of both variants. Other studies in Caucasian popu‐
lation, strong linkage disequilibrium between the exon 16 and exon 18 variants was demon‐
strated in patients with T2DM but was not shown in the control group [143].
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8.1.2. IRS-1gene
The utilization of insulin receptor substrate (IRS)-proteins (IRS-1 and IRS-2) emerged many
interactive proteins in the insulin signaling system. This  can be amplified or  attenuated
independently  insulin  binding  and  tyrosine  kinase  activity,  providing  an  extensible
mechanism  for  signal  transmission  in  multiple  cellular  backgrounds  [144].  Patient  with
T2DM with  IRS-1  variants  did  not  differ  in  their  degree  of  IR  compared  with  patients
without  known  IRS-1  polymorphisms.  However,  carriers  of  the  codon  972  variant  had
significantly lower plasma levels of fasting insulin and C-peptide [145, 146]. Many other
studies demonstrated several polymorphisms in the IRS-1 gene variant, a Gly-->Arg change
at  the  codon  972  may  contribute  in  impairment  of  insulin  secretion  and  increased  in
prevalence among patients with T2DM [146].
8.1.3. PC-1gene
In Swedish and Finnish people, the Q allele of the human glycoprotein PC-1 gene is associated
with surrogate measures of IR, but it may not be enough to increase the susceptibility to T2DM.
An observation showed there was no difference in the Q allele frequency between the patients
with T2DM and control group. There were higher fasting plasma glucose and 2 hours in QK
genotype siblings with diabetes compared with carrier of KK genotype. While in sibling with
QK genotype and without diabetes have higher fasting plasma glucose and insulin than KK
genotype carrier [147].
8.2. Glycogen synthase gene
An Xbal polymorphism has been described in the glycogen synthase gene associated with IR
[148]. More features of metabolic syndrome and increased susceptibility to T2DM were
described in sibling with rare A2 allele of discordant sib-pair analysis [149]. A set of polymor‐
phic microsatellite markers that span the genome was implemented in genotyping of families
with this condition to essence this approach [150].
8.2.1. Calpain 10 (CAPN10) gene
Calpain gene is cytoplasmic cystiene protease requiring calcium ions for activity. CAPN10
gene was proposed as susceptibility locus of T2DM based on the initial report of association
between the T2DM and CAPN10 gene [151]. It has been reported of association with T2DM in
Pima Indians [152], in African Americans [153] in Mexican Americans [154], in the Botnia area
of Finland, German patients [155] and in South Indians [156].
8.2.2. Foxo 1 gene
Insulin signalling downstream of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway is at
least in part controls glucose on β-cells mass and function. The activation of Akt is negatively
affected the proliferation and metabolism of Foxo transcription factors. The changes in Foxo
1 transcriptional activity are associated with nutritional alteration of β-cells. Glucose-stimu‐
lated insulin secretion acts through its own receptor as the predominant mediator of these
Treatment of Type 2 Diabetes78
changes in β-cells [157]. Ghrelin increases pancreatic β-cell proliferation and survival via
sequential activation of phosphatidylinositol-3 kinase (PI3K) and Akt ghrelin. It protects
pancreatic β-cells from lipotoxicity by inhibiting the nuclear translocation of Foxo1 [158].
8.3. Beta 3-adrenergic receptor gene
The energy balance by increasing in lipolysis and thermogenesis could be regulated by the
beta 3-adrenergic receptor (beta 3-AR) gene. The ability to gain weight and the early onset of
T2DM are associated with mutation in the beta 3-AR gene (Trp64Arg). But this is not in Dutch
population [159]. Many studies in different ethnic groups showed an association of beta3-AR
gene polymorphism with IR, obesity and its metabolic disorders such as T2DM, coronary heart
disease and hypertension [160].
8.3.1. TCF7L2
The risk alleles of TCF7L2 were associated with enhanced expression of this gene in human
islets as well as impaired insulin secretion both in vitro and in vivo. TCF7L2 has also been
linked to altered pancreatic islet morphology as exemplified by increased individual islet size
and altered α and β cell ratio/distribution within human islets [161]. TCF7L2 encodes the
transcription factor TCF4 which is related to Wnt signaling pathway and which plays a critical
role in the pathogenesis of T2DM. The risks of alleles in TCF7L2 were associated with hepatic
but not peripheral IR and enhanced the rate of hepatic glucose production in human [162].
This is indirectly disturbing beta cells function of the pancreas.
8.3.2. SCL30A8
SCL30A8 encodes the islet specific zinc transporter ZnT-8, which delivers zinc ions from
cytoplasm into intracellular insulin-containing granules and is implicated in insulin matura‐
tion and/or storage processes in β-cells [163]. The expression level of ZnT-8 was remarkably
down regulated in the pancreas of db/db and Akitamice in the early stage of diabetes. Global
SCL30A8 knockout mice demonstrated reduced plasma insulin, impaired glucose –stimulated
insulin secretion, and markedly reduced islet zinc content [164].
8.4. Others genetic syndromes associated with diabetes
Down syndrome, Klinefelter syndrome, Turner syndrome, Wolfram syndrome, Friedreicha‐
taxia, Huntington chorea, Laurence-Moon-Biedlsyndrome, Myotonicdystrophy, Porphyria
and Prader-Willi syndrome.
9. Drugs induced hyperglycemia and DM
Many pharmacologic and chemical agents can predispose, induce or precipitate hyperglyce‐
mia in normal subjects with high risk of T2DM or patients with IGT and DM. The individual
effect of each agent could be weak or strong and subsequently the new glycemic state will be
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variable from transient to permanent. There are many mechanisms to induce diabetes by
interfere with insulin production or secretion (e.g. Beta- Blockers), block insulin action (e.g.
Steroids), interfere with both insulin secretion and action (e.g. Thiazides), and finally increase
blood glucose using mechanisms independent of insulin’s actions (e.g. Nicotinic acid) [165].
Table 2 shows the most common drugs that used in clinical practice with the mechanism of
each drug or group.
Drugs Mechanisms Notes
Thiazide and thiazide like
drugs. Chlorothiazide
Chlorothalidone
Hydrocholorthiazide
Idapamide
Methyclothiazide
Metolazone
Decreases insulin release by hypokalemia
[167,168] and down regulation of PPARγ
Receptor.
Avoided in patients with DM and patients
at risk of hyperglycemia. Use small dose if
requires [167, 168].
*Spironolactone does not
cause IGT even at high
dosage [167].
In hypertensive elderly on Thiazide but
without DM, each 0.5meq/L reduction in
serum potassium was associated with 45%
higher risk of new DM [169].
Indapamide does not interfere with blood
sugar control in T2DM but higher doses
that cause potassium loss may cause
deterioration.
Increases aldosterone release and IR
[170,171].
Loop diuretics have been reported to
reduce glucose control to a lesser extent
than Thiazides [168].
Atypical antipsychotics
High risk
Clozapine
Olanzapine Wight gain [172, 173] and adiposity [174]
Risk of hyperglycemia is more in patients
with obesity, age, ethnic status, and certain
neuropsychiatric conditions [173].
Intermediate risk
Paliperidone
Quietiapine
Resperidone
Sympathetic stimulation [175].
Low risk
Aripiprazole Ziprasidone
Decrease insulin action [173] and increase IR
[176].
Unknown
Iloperidone
Potential Individual Polymorphisms in the
leptin gene and leptin receptor gene to
antipsychotic induced obesity [177].
Β- blockers
Atenolol
Metoprolol
Propranolol
Increase fasting glucose [178].
The risk of hyperglycemia is increased in
patient on B-blocker and thiazide diuretics
[180].
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*Carvidolol and nebivolol are
not associated with
hyperglycemia.
Impair insulin secretion [179]
Corticosteroids
Betamethasone acetate
Cortisone
Methylprednisolone
Hydrocortisone
Fludrocortisone
Hydrocortisone
Triamcinolone
Prednisolone
Dexamethasone
Decrease in both hepatic and extrahepatic
sensitivity to insulin [182]. Identify high risk patient of hyperglycemia.
Oral contraceptive pills Increase IR [182,183]. Risk of hyperglycemia is increased withhigher doses and longer duration therapy.
Megasterol acetate [181].
Monitor the blood glucose to optimize the
diabetes therapy by tablets or insulin to
avoid short and long term complications of
hyperglycemia.
Growth Hormone
Accelerated lipolysis resulting in increased
circulating non-esterified fatty acids levels
[184,185]. This may contribute to IR,
hyperinsulinemia and defective glycogen
synthesis [186].
Used as replacement therapy in patients
with GH deficiency.
Protease inhibitors
Atazanavir, Darunavir
Fosamprenavir
Indinavir
Nelfinavir
Ritonivir
Saquinavir
Tipranivir.
Etravirine
Maraviroc
Raltegravir
Inhibition of GLUT4
Transporter contributes to decrease
peripheral insulin sensitivity and induce IR.
[187].
Lipodystrophy and
Dyslipidaemia are major side effects of this
group [188].
Didanosine
Nucleoside reverse
transcriptase inhibitor
Causes β-cell injury by pancreatitis [189].
Used in treatment of HIV infection. The
risk is increased with high dose and in
combination with tenofovir [190].
Antibiotics
(Quinolone group)
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Drugs Mechanisms Notes
Gatifloxacin
Temafloxacin
Levofloxacin
Stimulation of insulin secretion by inhibition
of pancreatic beta-cell K(ATP) channels
causes hypoglycemia [192].
It may also cause hyperglycemia. [193].
Gatifloxacin was withdrawn from the
market because of this effect [193].
Levofloxacin has a small effect. [192].
Rifampicin
[191].
Possibly by augmenting intestinal
absorption of glucose.
It is an early phase of hyperglycemia and
disappeared after few days of treatment.
This effect in rat [194].
Tetracyclines
Tetracycline
chlortetracycline
Causes hyperglycemia.
\Calcineurin inhibitors
Cyclosporine
Impair the function β-cells by impairing
insulin gene expression [195-197].
The incidence of new onset DM was 14 to
16% augmented in the first post-
transplantation year, declining thereafter to
an annual incidence of 4 to 6%, similar to
the pre-transplantation baseline rate [205,
206].
Sirolimus
Tacrolimus
Cyclosporine
Direct β-cells toxicity [198-200].
Decreases in IS [201].
The cumulative incidence of new onset DM
was 24% at 3 yr after transplantation [205].
Impair insulin-mediated suppression of
hepatic glucose production [202].
May cause ectopic triglyceride deposition,
leading to IR [203, 204].
There is a synergetic effect of cyclosporine
to induce DM if given with other
diabetogenic drug [207].
The above aggravated by many modifiable
and non-modifiable risk factors [201].
Thalidomide
[208].
Decreases insulin-stimulated peripheral
glucose uptake by 31% (increased insulin
resistance)
Thalidomide, withdrawn for teratogenicity
and was reintroduced in 1997 as an
immunomodulator to treat erythema
nodosum leprosum.
Decreases glycogen synthesis by 48%.
Fish oil
or Omega -3 polyunsaturated
fatty acids (PUFAs).
PUFAs may affect glucose metabolism
through increased IS, but studies to date
have been inconclusive [209].
Among all adults who use natural
products, more than 37% report taking fish
oil or omega-3s.
[210].
Interferon α
[211].
Risk of hyperglycemia only in patient with
chronic hepatitis C infection.
Sustained virological responses reduce the
risk of developing glucose abnormalities,
especially in patients with normal glucose
baseline.
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Ritodrine [212]. Ritodrine induced hypokalemia. It is selective β2- adrenergic agonist usedfor premature labour.
Pentamidine
[213].
Inappropriate insulin release and toxicity to
the islet β-cells.
It may cause hypoglycemia, IGT and DM.
It is anti-protozoa agent.
These effects worsening with higher doses
prolong course and renal impairment.
Statins [214]. Impairing β-cell function and decreasingperipheral insulin sensitivity.
Elderly women and Asians are at particular
risk.
Nicotinamide
[215]. Enhanced gluconeogenesis.
Hyperglycemia may occur in both normal
subjects and in patients with DM.
Diazoxide [216]. Inhibits insulin secretion Used in treatment of insulinoma.
Inhibiting apoptosis, increases islet insulin
content, accompanied with ameliorated
glucose tolerance.
It may be useful in treatment and
prevention of DM.
diphenylhydantoin
[217]. Inhibits insulin secretion.
Hyperglycemia is more likely to develop in
subjects with other risk factors for DM.
L-Asparaginase
Non injury to β-cells [218].
In Rabbits, the anti-tumor enzyme, L-
asparaginase, is produced at least in part by
the suppression of insulin release [219].
It is transient hyperglycemia that ends
following stop the drug.
Vacor
Rodenticide poisoning
[220].
It has antineoplastic activity and cause
pancreatic β-cell damage.
Accidental ingestion by subjects causes
severe form of diabetes Ketoacidosis.
Total Parenteral Nutrition
These patients are often critically ill and are
administered preparations with high
glucose content [221].
It is associated with poor outcome in
severely ill patients [221,222].
Table 2. A modified and updated table of mechanisms of drugs induced hyperglycemia [166].
10. Gestational Diabetes Mellitus
Gestational diabetes mellitus (GDM) is a heterogeneous pathogenic condition affecting 2-5%
of all pregnant women during pregnancy [223, 224] in other data is 5-6% [225]. GDM and T2DM
share a common pathophysiological background, including β-cell dysfunction and IR [226,
227]. In addition, women with GDM are at increased risk of developing T2DM later in life
[226]. The pancreatic β- cells failure and impairment is the primary characteristic of GDM. In
this group of patients with diabetes, there is a genetic predisposition triggered by increased
IR during pregnancy leading to malfunction of the pancreatic β-cells [224]. The clustering of
the GDM within family members suggestive of genetic predisposition to the development of
this disease. Furthermore, women with MODY gene mutations are reported to have GDM
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more often [223,224]. In addition, the mutations in other genes include glucokinase (GCK),
HLA antigens, insulin receptor (INSR), insulin-like growth factor-2 (IGF2), HNF4A, insulin
gene (INS-VNTR), plasminogen activator inhibitor 1 (PAI-1), potassium inwardly rectifying
channel subfamily J, member 11 (KCNJ11), hepatocyte nuclear factor-4a (HNF4A) and 1α
(HNF1A) [224] suggest the susceptibility to increase the risk of GDM in certain patients.
The stimulators or the inducers of IR and phosphorylate insulin receptor substrate (IRS)
proteins are activated in uncontrollable method several kinases, including inhibitor of nuclear
factor ĸB kinase β (IKK β), c-Jun N-terminal kinase (JNK), mammalian target of rapamycin
(mTOR), protein kinase C (PKC) and ribosomal S6 protein kinase (S6K). Substance P is a potent
cytokine and is considered one of the crucial activators that contribute in the development of
IR by impairment of insulin signaling [225]. The genetic variants in TCF7L2 is the strongest
gene associated with GDM risk among other minor alleles of rs7903146 (TCF7L2), rs1225 5372
(TCF7L2), rs1799884 (-30G/A, GCK), rs5219 (E23K, KCNJ11), rs7754840 (CDKAL1), rs4402960
(IGF2BP2), rs10830963 (MTNR1B), rs1387153 (MTNR1B) and rs1801278 (Gly972Arg, IRS1)
significantly associated with a higher risk of GDM. There are 12 SNPs from 10 genes are
associated GDM [228].
The E23K polymorphism of KCNJ11 seems to predispose to GDM in Scandinavian women
[226] and the polymorphism of TCF7L2 (rs7903146 C/T) gene, and the G972R polymorphism
of the IRS1 gene, seems to predispose to GDM in Greek women [227]. In women of Han
nationality in north China, The defect in sulfonylurea receptor-1 (SUR1) gene (cc and AA) may
contribute to insulin hypersecretion, which might be the cause of increased body weight and
decreased IS and genotype cc of SUR1 is connected with severe type of GDM [229].
In animals but not in human, Galanin inhibits glucose-stimulated insulin release [230]. In the
human, the initial postprandial rise of glucose and insulin are suppressed by galanin admin‐
istration [231]. Galanin and IL-6 were found to be significantly associated with IR markers in
GDM, thus may play important roles in the regulation of glucose hemostasis [232].The higher
level of plasma galanin is a novel biomarker for the prediction of GDM [233].
In late pregnancy the relative proinsulin secretion is mainly related to IR and does not
necessarily reflect β-cell function. T2DM is not independently associated with hyperproinsu‐
linemia as measured by the proinsulin-to-C-peptide ratio. While, in pregnant women, the
increased in IR is associated with decreased proinsulin to C-peptide ratio, independently of
glucose tolerance status [234].
The islet amyloid pancreatic polypeptid hypersecretion is characteristic for pregnancy and
might partially decrease hyperinsulinemia in pregnancy by inhibiting insulin secretion [235].
The β- cells dysfunction and IR are the core in the pathogenesis of T2DM and both are mediated
by Adiponectin. Therefore, in late pregnancy the Adiponectin is an independent factor
correlated with β- cells dysfunction [236].
In pregnancy IR and GDM caused by the placental hormones and cytokines such as tumor
necrosis factor alpha (TNFα), resisten and leptin. All of these are secreted by placenta inde‐
pendently. The human chorionic somatomammotropin (HCS), cortisol, estrogen, progester‐
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one, and human placental growth hormone (hPGH) are important placental hormones. Severe
IR produced by overexpression of hPGH and the increase of the HCS throughout pregnancy
stimulates maternal pancreatic insulin release [237].
The fall of IS during pregnancy is counteracted by increase maternal insulin secretion to
maintain glucose control [238]. The insufficient insulin secretion to counteract the pregnancy-
related decrease in IS is contributing in development of DM [239]. Women at high risk of GDM
should have a prior conception plan to prevent DM by normalize body weight, regular physical
exercise, reducing excess intake of animal protein and soft drinks, planning of pregnancy in
younger ages, avoiding pollutant exposition and smoking cessation [240].
11. Uncommon diseases cause hyperglycemia and DM
11.1. Endocrine diseases
Acromegaly and hypercortisolism are frequently associated with IGT and T2DM. It is a
recognized finding of occurrence of secondary T2DM with many hormonal diseases (pituitary,
adrenal/or thyroid disease). Patients with Acromegaly have IR, both in the liver and in the
periphery displaying hyperinsulinemia and increased glucose turnover in the basal post-
absorptive states. There is increase in blood glucose level and free fatty acids due to stimulation
of gluconeogenesis and lipolysis. Although, insulin growth factor-1(IGF-1) level is increased
but it is unable to counteract IR induced by abnormal excess GH level. On the other hand, IS
primarily enhanced in the skeletal muscles by increased IGF-1. The excess of the GH and IGF-1
in patients with Acromegaly could be controlled by somatostatin analogues (SSAs) therapy in
most of the patients. On the contrast, the overall glucose tolerance might be complicated by
the inhibitory effect of SSAs on pancreatic insulin secretion.
The visceral obesity and IR are induced by hypercortisolemia. It also leads to hyperglycemia
and reduced glucose tolerance, determines IR and stimulates hepatic gluconeogenesis and
glycogenolysis. The hyperglycemia is due to decreased insulin secretion in patients with
neuroendocrine tumors (NETs), patients with pancreatic surgery and in those with pheochro‐
mocytoma. While in somatostatinoma or gluconoma the hyperglycemia is related to alteration
in the counterbalance between these hormones. In the symptomatic treatment of NETs, the
SSAs represent a valid therapeutic choice and it may have a significant impact on the preva‐
lence of glucose metabolism imbalance.
Hyperthyroidism is the principally cause of hyperglycemia among thyroid disorders [241]. IR
is associated positively with abnormal increase in the thyroid hormone levels [242]. The
uncontrolled diabetes in patient with diabetes developing thyrotoxicosis is related to the
stimulation of hepatic glucose production by thyroid hormones acting via a sympathetic
pathway from the hypothalamus and FT3 influenced the transcriptional regulators of meta‐
bolic and mitochondrial genes may contribute to the development of IR. In contrast, hypo‐
thyroidism is linked to decreased IS. The thyroid hormones have insulin antagonistic effects
at the liver that lead to an increase in glucose hepatic output, via an enhanced rate of gluco‐
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neogenesis and glycogenolysis. Lipid metabolism (lipogenesis and lipolysis) are stimulated
by FT3 further aggravating the dysregulation of liver glucose and lipid metabolism predispose
to IR There are several genes are involved in gluconeogenesis, glycogen metabolism, insulin
signaling and many hepatic glucogenic enzymes are regulated by thyroid hormones. The
thyroid hormones also could cause an increase in hepatic glucose output, through increased
hepatic expression of the glucose transporter GLUT2 [243].
11.2. Polycystic ovary syndrome
The features of PCOS are hyperinsulinemia, IR and hyperandrogenesim. The later present‐
ed in  those  patients  with  hirsutism,  acne,  irregular  periods  and reproductive  disorders.
These features are more marked and severe in obese females and the combination of both
(these features with obesity) have a synergistic effect on increased insulin secretion by β-
cells and development of compensatory hyperinsulinemia. Subsequently, with the decline
of the β-cell  compensatory response a relative or absolute insulin secretion and produc‐
tion insufficiency develops which may lead to dysglycemia (IFG, IGT and T2DM). There‐
fore, it is well-known that PCOS and IR are considered risk factors for GDM [244]. This
risk is increased in obese females, presence of family history of T2DM and to the severity
of high androgenic activity. Therefore, the dysglycemia could occur in earlier age group
than normal population. It could be in the 3rd or 4th decade of life and it is approximately
5 to 10 folds higher than normal population. No doubt, it is higher compared with age and
weight matched control age group [245].
11.3. Pancreatic damage or β-cell damage of the pancreas
Chronic alcoholism and tropical calcified pancreatitis are most commonly associated with
diabetes [247]. Pancreatic exocrine disease associated with hyperglycemia or DM has a unique
clinical and metabolic form. It is painless occasionally and malabsorption occurs after clinical
hyperglycemia or DM following failure or impairment of endocrine and exocrine pancreatic
function of both α and β cells [246]
11.4. Hereditary hemochromatosis
Iron overload and excessive tissues deposition of iron including the pancreas. It is an autosomal
recessive genetic disorder caused by a mutation in the HFE gene located on the short arm of
chromosome 6. Approximately 50% of patients diagnosed with hemochromatosis will have
either type 1 or T2DM [248].
11.5. Cystic fibrosis
Diabetes Mellitus is the most common morbidity in patients with cystic fibrosis (CF). It occurs
in about 20% of adolescent and 40-50% of adults with this disease. CF primarily caused by
insulin insufficiency. However, there is a role for IR in acute and chronic stages of this disease
due to fluctuation level of insulin. DM has a unique distinct entity in patient with CF because
it has mixed features of TIDM and T2DM [249].
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Other causes of damage of the pancreas are toxins like alcohol, surgical resection of the
pancreas and pancreatic cancer.
11.6. Smoking
There are several studies suggestive of smoking is a risk factor for T2DM, it is an independent
and modifiable risk. The early weight gain following smoking cessation is far more beneficial
compared with the long term effect of smoking. This weight gain could increase the risk of
diabetes [250-252]. Smoking deteriorates glucose metabolism and it is considered a possible a
risk factor for development of IR and subsequently T2DM [253]. Smoking is also through a
body mass index independent mechanism increasing the risk of T2DM [254, 255]. Pancreatic
damage by toxic agents cause insufficient insulin secretion and development of the disease.
Tobacco is one of the toxic agent to the human body and organ damage; on the pancreas it is
also considered a risk factor of pancreatic cancer and chronic pancreatitis [256].
11.7. Prematurity and birth weight
Hofman PL in 2004 reported an association between low birth weight, commonly a reflection
of an adverse in utero environment, and the subsequent development of diseases such as
T2DM and hypertension in later life is now generally accepted as is an association between an
adverse perinatal environment and a permanent reduction in IS [257, 258].This concept was
changed in other report by the evidence has accumulated that small for gestational age children
have long-term adult health consequences including obesity, T2DM, hypertension, coronary
artery disease and stroke. This increased risk of later adult disease is likely a consequence of
an early, persistent reduction in IS [259]. Reduced fetal growth is associated with increased
risk of diabetes and suggested a specific association with thinness at birth [260]. Prevalence of
T2DM and IGT depended on the synergic effect of thin body size at birth and obesity during
adulthood [261]. IGT and T2DM are early signs and indications of growth retardation in early
life. The raise in plasma levels of 32-33 split proinsulin is closely related to growth retardation
and reflects the β-cells dysfunction [262]. A review and analysis of 14 studies low birth weight
(<2,500 g), as compared with a birth weight of >/=2,500 g, was associated with increased risk
of T2DM. The risk is the same in high birth weight (>4,000 g), as compared with a birth weight
of (</=4,000 g) [263]. The two strongest predictor factors for development of T2DM in adult life
are low birth weight and abdominal obesity. The risk of T2DM in Chinese adults is inversely
correlated to birth weight. Subjects with high risk of developing hypertension and abdominal
obesity are those with the lowest or highest birth weight [264].
12. Conclusion
The evolution of T2DM requires the presence of defects in both insulin secretion and insulin
action, and both of these defects can have a genetic and an acquired component. There are
many discovered complex alterations in adipose tissue secretion of cytokines, adipokines, and
chemokines and immune cell composition observed in adipose tissue-related pathologies such
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as obesity and IR. The later is a nearly universal finding in patients with established disease.
There are many recognized genes involved in β-cell development, function and regulation.
These could lead to disorders in insulin secretion, IR and glucose sensing. Physicians should
be aware about the potential drugs contribute to the development of hyperglycemia and
diabetes. Ladies at high risk of GDM should be identified and screened for diabetes before
conception and to be followed after delivery. Early identification and diagnosis of many
medical conditions and other risk factors could induce hyperglycemia or precipitate a pre-
existing condition of DM.
The above demonstrated a wide range of research in this area that should be encouraged to
improve our understanding of the disease. T2DM is a complex interaction between genetics,
cytokines, immune cells and tissues during inflammatory responses with obesity, insulin
function, IR and β-cells failure. Subsequently this could help in discovery new drugs to treat
T2DM that could interfere or stop any stage of these mechanisms at molecular or genetic level.
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